Antoni Wiedlocha funded by the EEA Poland-Norway grants
Antoni Wiedlocha
The proposal "Novel targeted therapy based on dual warhead conjugates against FGFR dependent cancers", with senior scientist Antoni Wiedlocha at Department of Molecular Cell Biology, Institute for Cancer Research, as Norwegian partner and professor Jacek Otlewski at the University of Wroclaw as Polish parther, has been awarded funding from the EEA Poland-Norway grants under the "Applied Research" programme.
Links:
From the National Centre for Research and Development in Poland:
From major journals, first or last author from the Institute for Cancer Research
Chen Y, He L, Ianevski A, Ayuda-Durán P, Potdar S, Saarela J, Miettinen JJ, Kytölä S, Miettinen S, Manninen M, Heckman CA, Enserink JM, Wennerberg K, Aittokallio T(2023) Robust scoring of selective drug responses for patient-tailored therapy selection Nat Protoc(in press) DOI 10.1038/s41596-023-00903-x, PubMed 37996540
Al Outa A, Hicks S, Thambawita V, Andresen S, Enserink JM, Halvorsen P, Riegler MA, Knævelsrud H(2023) CELLULAR, A Cell Autophagy Imaging Dataset Sci Data, 10(1), 806 DOI 10.1038/s41597-023-02687-x, PubMed 37973836
García-Díaz N, Wei Q, Taskén K(2023) Small molecule inhibitors targeting regulatory T cells for cancer treatment Eur J Immunol, e2350448(in press) DOI 10.1002/eji.202350448, PubMed 37937687
Hindi N, Razak A, Rosembaum E, Jonczak E, Hamacher R, Rutkowski P, Bhadri VA, Skryd A, Brahmi M, Alshibany A, Jagodzinska-Mucha P, Bauer S, Connolly E, Gelderblom H, Boye K, Henon C, Bae S, Bogefors K, Vincenzi B, Martinez-Trufero J, Lopez-Martin JA, Redondo A, Valverde C, Blay JY, Moura DSet al.(2023) Efficacy of immune checkpoint inhibitors in alveolar soft-part sarcoma: results from a retrospective worldwide registry ESMO Open, 8(6), 102045(in press) DOI 10.1016/j.esmoop.2023.102045, PubMed 38016251
Børø S, Thoresen S, Boge Brant S, Helland Å(2023) Initial investigation of using Norwegian health data for the purpose of external comparator arms - an example for non-small cell lung cancer Acta Oncol, 62(12), 1642-1648 DOI 10.1080/0284186X.2023.2264484, PubMed 37801361
Chen Y, He L, Ianevski A, Ayuda-Durán P, Potdar S, Saarela J, Miettinen JJ, Kytölä S, Miettinen S, Manninen M, Heckman CA, Enserink JM, Wennerberg K, Aittokallio T(2023) Robust scoring of selective drug responses for patient-tailored therapy selection Nat Protoc(in press) DOI 10.1038/s41596-023-00903-x, PubMed 37996540